Innovative Breakthroughs and Clinical Application Prospects of Targeted Antibodies in Tumor Immunotherapy

Molecular Design and Mechanism of Action of Targeted Antibodies

Targeted antibodies are a class of recombinant immunoglobulins capable of specifically recognizing and binding to key molecules on the surface of tumor cells or in the tumor microenvironment, such as antigen receptors and signaling pathway proteins. Their core advantage lies in achieving precise recognition of tumor cells through high-affinity binding, thereby mobilizing the body's immune system or directly delivering cytotoxic drugs. Common engineering strategies include humanization, affinity maturation, and Fc fragment optimization to reduce immunogenicity and enhance effector functions. For example, trastuzumab-class drugs targeting the Her-2 antigen inhibit cell proliferation by blocking the downstream PI3K/Akt signaling pathway while inducing antibody-dependent cell-mediated cytotoxicity (ADCC), playing an important role in the treatment of breast cancer.

Antibody-Drug Conjugates: Precise Delivery and Synergistic Killing

Antibody-drug conjugates (ADCs) achieve targeted drug delivery by conjugating highly active cytotoxic small molecules to targeting antibodies via cleavable or non-cleavable linkers. This technology effectively overcomes the limitations of non-specific distribution and systemic toxicity associated with traditional chemotherapy. Currently, more than ten ADC drugs have been approved for marketing, covering hematologic malignancies (such as CD33 and CD22 targets) and solid tumors (such as Her-2 and Trop-2 targets). The design of ADCs requires comprehensive consideration of antibody specificity, linker stability, drug-to-antibody ratio (DAR), and drug release kinetics. Clinical studies have shown that next-generation ADCs, through site-specific conjugation technology and hydrophilic linker improvements, have significantly enhanced the therapeutic window and in vivo stability. It should be noted that adverse events such as neutropenia, thrombocytopenia, and interstitial pneumonia associated with ADCs still require strengthened monitoring in clinical use.

Bispecific Antibodies and Multi-Target Synergistic Strategies

Bispecific antibodies can simultaneously bind to tumor-associated antigens and immune effector cells (such as CD3+ T cells), forming immune synapses to achieve direct T cell activation and tumor cell killing. Taking CD20×CD3 bispecific antibodies as an example, they bridge B-cell lymphomas and T cells, bypassing MHC restriction and enhancing the clearance of tumors with low antigen expression. In recent years, some bispecific antibody products have achieved breakthrough efficacy in relapsed/refractory multiple myeloma and acute lymphoblastic leukemia. However, cytokine release syndrome (CRS) and neurotoxicity remain major challenges in their clinical application. Researchers are exploring optimization of safety through adjusting affinity, introducing masked antibody formats (such as half-life extension and conditional activation), and combining with immune checkpoint inhibitors.

Clinical Status and Future Trends of Targeted Antibodies in Solid Tumor Therapy

Currently, targeted antibody drugs cover multiple tumor types including lung cancer, colorectal cancer, gastric cancer, liver cancer, and melanoma. For example, programmed death receptor antibodies targeting PD-1/PD-L1 immune checkpoints have shown durable responses in various advanced solid tumors. In addition, antibodies targeting EGFR, VEGF, and c-Met can be combined with chemotherapy or targeted drugs for patient populations with specific gene mutations or high expression. With the advancement of precision medicine, liquid biopsy technology has made companion diagnostics for targeted antibodies more convenient. In the future, targeted antibodies are expected to continue evolving toward multimodal combinations (such as ADC + immune checkpoint inhibitors, bispecific antibodies + cell therapy) and intelligentization (such as pH-responsive antibodies and probodies), but vigilance must be maintained against drug resistance caused by target antigen downregulation, and real-world studies are needed to verify the benefits and risks of long-term medication.